Novartis

Summary

In 1996 was created Novartis, which is appeared as Corporate Investor. The company was established in Europe in Switzerland. The leading representative office of defined Corporate Investor is situated in the Basel.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis, startups are often financed by 5AM Ventures, UPMC, Threshold. The meaningful sponsors for the fund in investment in the same round are MPM Capital, GV, Atlas Venture. In the next rounds fund is usually obtained by GV, Temasek Holdings, Pontifax AgTech.

This organization was formed by Joerg Reinhardt. The overall number of key employees were 44.

The usual things for fund are deals in the range of more than 100 millions dollars. The increased amount of exits for fund were in 2018. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. Opposing the other organizations, this Novartis works on 1 percentage points more the average amount of lead investments. The real fund results show that this Corporate Investor is 11 percentage points less often commits exit comparing to other companies. The fund is constantly included in less than 2 deals per year.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular portfolio startups of the fund, we may highlight Proteus Digital Health, Cota Healthcare, Caribou Biosciences. We can highlight the next thriving fund investment areas, such as Medical, Therapeutics. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.